Akash Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Akash Kumar has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Kate Im
MyOme Inc., Menlo Park, USA
3 shared publicationsMatthew Rabinowitz
MyOme Inc., Menlo Park, USA
3 shared publicationsBrynn Levy
MyOme Inc., Menlo Park, USA
2 shared publicationsDonna Hongo
MyOme Inc., Menlo Park, USA
2 shared publicationsAmaia Lasa‐Aranzasti
Medicine Genetics Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari Barcelona Spain
1 shared publication- Aman Chandra Kaushik
Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China
1 shared publication
Latest Publications
- Open Access
- 29 March 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (8) , e64048
Expanding the SIAH1‐Associated Phenotypic Spectrum: Insights From Loss‐of‐Function Variants
SIAH1 encodes for a RING‐type E3 ubiquitin ligase involved in protein ubiquitination. More specifically, it positively regulates Wnt signaling through promoting the accumulation of β‐catenin and mediates ubiquitination and degradation of Akt3 in neural development. Heterozygous de novo missense pathogenic variants in SIAH1 have been described in five unrelated individuals and are associated with developmental delay, hypotonia, and dysmorphic features. In this report, we present additional individuals from eight unrelated families and their clinical and genetic findings. We identified two missense and six predicted loss‐of‐function variants. Motor and speech delay and intellectual disabilities of varying severity were observed in all individuals. Neurodevelopmental issues, as well as infantile hypotonia and facial dysmorphism, were observed in the majority of individuals. Hearing loss, gastroesophageal reflux disease or other gastrointestinal issues, endocrinology abnormalities, and recurrent infections were observed in over 50% of individuals. This study expands the phenotypic spectrum of this syndrome and emphasizes the diverse impact of SIAH1 variation on multi‐system clinical manifestations.
- 29 March 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (8) , e64048
Open AccessExpanding the SIAH1‐Associated Phenotypic Spectrum: Insights From Loss‐of‐Function Variants
SIAH1 encodes for a RING‐type E3 ubiquitin ligase involved in protein ubiquitination. More specifically, it positively regulates Wnt signaling through promoting the accumulation of β‐catenin and mediates ubiquitination and degradation of Akt3 in neural development. Heterozygous de novo missense pathogenic variants in SIAH1 have been described in five unrelated individuals and are associated with developmental delay, hypotonia, and dysmorphic features. In this report, we present additional individuals from eight unrelated families and their clinical and genetic findings. We identified two missense and six predicted loss‐of‐function variants. Motor and speech delay and intellectual disabilities of varying severity were observed in all individuals. Neurodevelopmental issues, as well as infantile hypotonia and facial dysmorphism, were observed in the majority of individuals. Hearing loss, gastroesophageal reflux disease or other gastrointestinal issues, endocrinology abnormalities, and recurrent infections were observed in over 50% of individuals. This study expands the phenotypic spectrum of this syndrome and emphasizes the diverse impact of SIAH1 variation on multi‐system clinical manifestations.
- Open Access
- 10 June 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-11
Implementation of Nanopore sequencing as a pragmatic workflow for copy number variant confirmation in the clinic
Background: Diagnosis of rare genetic diseases can be a long, expensive and complex process, involving an array of tests in the hope of obtaining an actionable result. Long-read sequencing platforms offer the opportunity to make definitive molecular diagnoses using a single assay capable of detecting variants, characterizing methylation patterns, resolving complex rearrangements, and assigning findings to long-range haplotypes. Here, we demonstrate the clinical utility of Nanopore long-read sequencing by validating a confirmatory test for copy number variants (CNVs) in neurodevelopmental disorders and illustrate the broader applications of this platform to assess genomic features with significant clinical implications. Methods: We used adaptive sampling on the Oxford Nanopore platform to sequence 25 genomic DNA samples and 5 blood samples collected from patients with known or false-positive copy number changes originally detected using short-read sequencing. Across the 30 samples (a total of 50 with replicates), we assayed 35 known unique CNVs (a total of 55 with replicates) and one false-positive CNV, ranging in size from 40 kb to 155 Mb, and assessed the presence or absence of suspected CNVs using normalized read depth. Results: Across 50 samples (including replicates) sequenced on individual MinION flow cells, we achieved an average on-target mean depth of 9.5X and an average on-target read length of 4805 bp. Using a custom read depth-based analysis, we successfully confirmed the presence of all 55 known CNVs (including replicates) and the absence of one false-positive CNV. Using the same CNV-targeted data, we compared genotypes of single nucleotide variant loci to verify that no sample mix-ups occurred between assays. For one case, we also used methylation detection and phasing to investigate the parental origin of a 15q11.2-q13 duplication with implications for clinical prognosis. Conclusions: We present an assay that efficiently targets genomic regions to confirm clinically relevant CNVs with a concordance rate of 100%. Furthermore, we demonstrate how integration of genotype, methylation, and phasing data from the Nanopore sequencing platform can potentially simplify and shorten the diagnostic odyssey.
- 10 June 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-11
Open AccessImplementation of Nanopore sequencing as a pragmatic workflow for copy number variant confirmation in the clinic
Background: Diagnosis of rare genetic diseases can be a long, expensive and complex process, involving an array of tests in the hope of obtaining an actionable result. Long-read sequencing platforms offer the opportunity to make definitive molecular diagnoses using a single assay capable of detecting variants, characterizing methylation patterns, resolving complex rearrangements, and assigning findings to long-range haplotypes. Here, we demonstrate the clinical utility of Nanopore long-read sequencing by validating a confirmatory test for copy number variants (CNVs) in neurodevelopmental disorders and illustrate the broader applications of this platform to assess genomic features with significant clinical implications. Methods: We used adaptive sampling on the Oxford Nanopore platform to sequence 25 genomic DNA samples and 5 blood samples collected from patients with known or false-positive copy number changes originally detected using short-read sequencing. Across the 30 samples (a total of 50 with replicates), we assayed 35 known unique CNVs (a total of 55 with replicates) and one false-positive CNV, ranging in size from 40 kb to 155 Mb, and assessed the presence or absence of suspected CNVs using normalized read depth. Results: Across 50 samples (including replicates) sequenced on individual MinION flow cells, we achieved an average on-target mean depth of 9.5X and an average on-target read length of 4805 bp. Using a custom read depth-based analysis, we successfully confirmed the presence of all 55 known CNVs (including replicates) and the absence of one false-positive CNV. Using the same CNV-targeted data, we compared genotypes of single nucleotide variant loci to verify that no sample mix-ups occurred between assays. For one case, we also used methylation detection and phasing to investigate the parental origin of a 15q11.2-q13 duplication with implications for clinical prognosis. Conclusions: We present an assay that efficiently targets genomic regions to confirm clinically relevant CNVs with a concordance rate of 100%. Furthermore, we demonstrate how integration of genotype, methylation, and phasing data from the Nanopore sequencing platform can potentially simplify and shorten the diagnostic odyssey.
- Open Access
- 21 March 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (3) , 513-516
Whole-genome risk prediction of common diseases in human preimplantation embryos
Preimplantation genetic testing (PGT) of in-vitro-fertilized embryos has been proposed as a method to reduce transmission of common disease; however, more comprehensive embryo genetic assessment, combining the effects of common variants and rare variants, remains unavailable. Here, we used a combination of molecular and statistical techniques to reliably infer inherited genome sequence in 110 embryos and model susceptibility across 12 common conditions. We observed a genotype accuracy of 99.0–99.4% at sites relevant to polygenic risk scoring in cases from day-5 embryo biopsies and 97.2–99.1% in cases from day-3 embryo biopsies. Combining rare variants with polygenic risk score (PRS) magnifies predicted differences across sibling embryos. For example, in a couple with a pathogenic BRCA1 variant, we predicted a 15-fold difference in odds ratio (OR) across siblings when combining versus a 4.5-fold or 3-fold difference with BRCA1 or PRS alone. Our findings may inform the discussion of utility and implementation of genome-based PGT in clinical practice.
- 21 March 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (3) , 513-516
Open AccessWhole-genome risk prediction of common diseases in human preimplantation embryos
Preimplantation genetic testing (PGT) of in-vitro-fertilized embryos has been proposed as a method to reduce transmission of common disease; however, more comprehensive embryo genetic assessment, combining the effects of common variants and rare variants, remains unavailable. Here, we used a combination of molecular and statistical techniques to reliably infer inherited genome sequence in 110 embryos and model susceptibility across 12 common conditions. We observed a genotype accuracy of 99.0–99.4% at sites relevant to polygenic risk scoring in cases from day-5 embryo biopsies and 97.2–99.1% in cases from day-3 embryo biopsies. Combining rare variants with polygenic risk score (PRS) magnifies predicted differences across sibling embryos. For example, in a couple with a pathogenic BRCA1 variant, we predicted a 15-fold difference in odds ratio (OR) across siblings when combining versus a 4.5-fold or 3-fold difference with BRCA1 or PRS alone. Our findings may inform the discussion of utility and implementation of genome-based PGT in clinical practice.
- 28 October 2021
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 385 (18) , 1726-1727
Use of Polygenic Scores to Select Embryos
Turley et al. (July 1 issue)1 state that MyOme “appears” to currently provide embryo selection using polygenic scores (ESPS) for nondisease traits. Although it may have appeared to be so, it is in fact not the case. Their statement was based on archived draft materials. We are conducting free-to-participant studies to assess the utility and tractability of ESPS. Although some participants have sought information on traits such as educational attainment, we determined that these issues distract from our health-focused conversation and mission. We generally agree with the recommendations of Turley et al. regarding messaging, augmented by an additional explanation of limitations. Nonetheless, feedback from our study has been positive; couples appreciate and feel empowered by the additional information, especially when the polygenic score modulates an increased family-history risk.
- 28 October 2021
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 385 (18) , 1726-1727
Use of Polygenic Scores to Select Embryos
Turley et al. (July 1 issue)1 state that MyOme “appears” to currently provide embryo selection using polygenic scores (ESPS) for nondisease traits. Although it may have appeared to be so, it is in fact not the case. Their statement was based on archived draft materials. We are conducting free-to-participant studies to assess the utility and tractability of ESPS. Although some participants have sought information on traits such as educational attainment, we determined that these issues distract from our health-focused conversation and mission. We generally agree with the recommendations of Turley et al. regarding messaging, augmented by an additional explanation of limitations. Nonetheless, feedback from our study has been positive; couples appreciate and feel empowered by the additional information, especially when the polygenic score modulates an increased family-history risk.
- 28 March 2019
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 179 (6) , 966-977
Extracutaneous manifestations in phacomatosis cesioflammea and cesiomarmorata: Case series and literature review
Phacomatosis pigmentovascularis (PPV) comprises a family of rare conditions that feature vascular abnormalities and melanocytic lesions that can be solely cutaneous or multisystem in nature. Recently published work has demonstrated that both vascular and melanocytic abnormalities in PPV of the cesioflammea and cesiomarmorata subtypes can result from identical somatic mosaic activating mutations in the genesGNAQandGNA11. Here, we present three new cases of PPV with features of the cesioflammea and/or cesiomarmorata subtypes and mosaic mutations inGNAQorGNA11. To better understand the risk of potentially occult complications faced by such patients we additionally reviewed 176 cases published in the literature. We report the frequency of clinical findings, their patterns of co‐occurrence as well as published recommendations for surveillance after diagnosis. Features assessed include: capillary malformation; dermal and ocular melanocytosis; glaucoma; limb asymmetry; venous malformations; and central nervous system (CNS) anomalies, such as ventriculomegaly and calcifications. We found that ocular findings are common in patients with phacomatosis cesioflammea and cesiomarmorata. Facial vascular involvement correlates with a higher risk of seizures (p = .0066). Our genetic results confirm the role of mosaic somatic mutations inGNAQandGNA11in phacomatosis cesioflammea and cesiomarmorata. Their clinical and molecular findings place these conditions on a clinical spectrum encompassing otherGNAQandGNA11related disorders and inform recommendations for their management.
- 28 March 2019
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 179 (6) , 966-977
Extracutaneous manifestations in phacomatosis cesioflammea and cesiomarmorata: Case series and literature review
Phacomatosis pigmentovascularis (PPV) comprises a family of rare conditions that feature vascular abnormalities and melanocytic lesions that can be solely cutaneous or multisystem in nature. Recently published work has demonstrated that both vascular and melanocytic abnormalities in PPV of the cesioflammea and cesiomarmorata subtypes can result from identical somatic mosaic activating mutations in the genesGNAQandGNA11. Here, we present three new cases of PPV with features of the cesioflammea and/or cesiomarmorata subtypes and mosaic mutations inGNAQorGNA11. To better understand the risk of potentially occult complications faced by such patients we additionally reviewed 176 cases published in the literature. We report the frequency of clinical findings, their patterns of co‐occurrence as well as published recommendations for surveillance after diagnosis. Features assessed include: capillary malformation; dermal and ocular melanocytosis; glaucoma; limb asymmetry; venous malformations; and central nervous system (CNS) anomalies, such as ventriculomegaly and calcifications. We found that ocular findings are common in patients with phacomatosis cesioflammea and cesiomarmorata. Facial vascular involvement correlates with a higher risk of seizures (p = .0066). Our genetic results confirm the role of mosaic somatic mutations inGNAQandGNA11in phacomatosis cesioflammea and cesiomarmorata. Their clinical and molecular findings place these conditions on a clinical spectrum encompassing otherGNAQandGNA11related disorders and inform recommendations for their management.
- Open Access
- 1 January 2017
- Published by Elsevier in Informatics in Medicine Unlocked
- Vol. 7, 34-38
Internal transcribed spacer sequence database of plant fungal pathogens: PFP-ITSS database
- 1 January 2017
- Published by Elsevier in Informatics in Medicine Unlocked
- Vol. 7, 34-38
Open AccessInternal transcribed spacer sequence database of plant fungal pathogens: PFP-ITSS database